跳至主要内容
临床试验/NCT00079794
NCT00079794已完成2 期

Iscar for Supplemental Care in Stage IV Lung Cancer

National Center for Complementary and Integrative Health (NCCIH)2 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2001年9月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
36
试验地点
2

研究概览

简要总结

The purpose of this study it to determine whether supplemental treatment with Iscar improves immune function and quality of life among Stage IV non-small cell lung carcinoma patients receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant extract of mistletoe. this preparation is already in use in Europe and its use in the US is likely to increase as cancer patients continue to seek alternative therapies.

详细描述

See Brief Summary

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Stage IV NSCLC patients who receive standard chemotherapy
  • Exclusion criteria:
  • Known allergy to Viscum Album L.
  • Concomitant use of other mistletoe products
  • Concomitant use of mushroom glucan and proteoglycan extracts
  • Concomitant use of thymus extract products
  • Inability to self-report quality of life utilizing assessment tools
  • Ongoing steroid or ACTH therapy
  • Co-morbid immunocompromised state
  • Pregnancy
  • Participation in other clinical trials

排除标准

  • 未提供

研究者

研究点 (2)

Loading locations...

相似试验